SLNO Q1 2025 Earnings — Soleno Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

SLNOSoleno Therapeutics, Inc.

$2B

Q1 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$46M

Net Income

-$44M

EPS (Diluted)

$-0.95

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$33M

Free Cash Flow

-$33M

Stock-Based Comp.

$15M

Balance Sheet

Total Assets

$318M

Total Liabilities

$86M

Stockholders' Equity

$232M

Cash & Equivalents

$81M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$46M	-$23M	-94.9%
Net Income	-$44M	-$21M	-104.6%